Cargando…
Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy
Chronic obstructive pulmonary disease (COPD) is considered one of the leading causes of mortality. Cardiovascular comorbidities are diagnosed often in COPD patients, not only because of the common risk factors these two diseases share, but also because of the systemic inflammation which characterize...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301030/ https://www.ncbi.nlm.nih.gov/pubmed/37374082 http://dx.doi.org/10.3390/life13061299 |
_version_ | 1785064716044861440 |
---|---|
author | Papaporfyriou, Anastasia Bartziokas, Konstantinos Gompelmann, Daniela Idzko, Marco Fouka, Evangelia Zaneli, Stavrina Bakakos, Petros Loukides, Stelios Papaioannou, Andriana I. |
author_facet | Papaporfyriou, Anastasia Bartziokas, Konstantinos Gompelmann, Daniela Idzko, Marco Fouka, Evangelia Zaneli, Stavrina Bakakos, Petros Loukides, Stelios Papaioannou, Andriana I. |
author_sort | Papaporfyriou, Anastasia |
collection | PubMed |
description | Chronic obstructive pulmonary disease (COPD) is considered one of the leading causes of mortality. Cardiovascular comorbidities are diagnosed often in COPD patients, not only because of the common risk factors these two diseases share, but also because of the systemic inflammation which characterizes COPD and has deleterious effects in the cardiovascular system. The comorbid cardiovascular diseases in COPD result in several difficulties in the holistic treatment of these patients and affect outcomes such as morbidity and mortality. Several studies have reported that mortality from cardiovascular causes is common among COPD patients, while the risk for acute cardiovascular events increases during COPD exacerbations and remains high for a long time even after recovery. In this review, we focus on the prevalence of cardiovascular comorbidities in COPD patients, presenting the evidence regarding the interaction of the pathophysiological pathways which characterize each disease. Furthermore, we summarize information regarding the effects of cardiovascular treatment on COPD outcomes and vice versa. Finally, we present the current evidence regarding the impact of cardiovascular comorbidities on exacerbations, quality of life and survival of COPD patients. |
format | Online Article Text |
id | pubmed-10301030 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103010302023-06-29 Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy Papaporfyriou, Anastasia Bartziokas, Konstantinos Gompelmann, Daniela Idzko, Marco Fouka, Evangelia Zaneli, Stavrina Bakakos, Petros Loukides, Stelios Papaioannou, Andriana I. Life (Basel) Review Chronic obstructive pulmonary disease (COPD) is considered one of the leading causes of mortality. Cardiovascular comorbidities are diagnosed often in COPD patients, not only because of the common risk factors these two diseases share, but also because of the systemic inflammation which characterizes COPD and has deleterious effects in the cardiovascular system. The comorbid cardiovascular diseases in COPD result in several difficulties in the holistic treatment of these patients and affect outcomes such as morbidity and mortality. Several studies have reported that mortality from cardiovascular causes is common among COPD patients, while the risk for acute cardiovascular events increases during COPD exacerbations and remains high for a long time even after recovery. In this review, we focus on the prevalence of cardiovascular comorbidities in COPD patients, presenting the evidence regarding the interaction of the pathophysiological pathways which characterize each disease. Furthermore, we summarize information regarding the effects of cardiovascular treatment on COPD outcomes and vice versa. Finally, we present the current evidence regarding the impact of cardiovascular comorbidities on exacerbations, quality of life and survival of COPD patients. MDPI 2023-05-31 /pmc/articles/PMC10301030/ /pubmed/37374082 http://dx.doi.org/10.3390/life13061299 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Papaporfyriou, Anastasia Bartziokas, Konstantinos Gompelmann, Daniela Idzko, Marco Fouka, Evangelia Zaneli, Stavrina Bakakos, Petros Loukides, Stelios Papaioannou, Andriana I. Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy |
title | Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy |
title_full | Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy |
title_fullStr | Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy |
title_full_unstemmed | Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy |
title_short | Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy |
title_sort | cardiovascular diseases in copd: from diagnosis and prevalence to therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301030/ https://www.ncbi.nlm.nih.gov/pubmed/37374082 http://dx.doi.org/10.3390/life13061299 |
work_keys_str_mv | AT papaporfyriouanastasia cardiovasculardiseasesincopdfromdiagnosisandprevalencetotherapy AT bartziokaskonstantinos cardiovasculardiseasesincopdfromdiagnosisandprevalencetotherapy AT gompelmanndaniela cardiovasculardiseasesincopdfromdiagnosisandprevalencetotherapy AT idzkomarco cardiovasculardiseasesincopdfromdiagnosisandprevalencetotherapy AT foukaevangelia cardiovasculardiseasesincopdfromdiagnosisandprevalencetotherapy AT zanelistavrina cardiovasculardiseasesincopdfromdiagnosisandprevalencetotherapy AT bakakospetros cardiovasculardiseasesincopdfromdiagnosisandprevalencetotherapy AT loukidesstelios cardiovasculardiseasesincopdfromdiagnosisandprevalencetotherapy AT papaioannouandrianai cardiovasculardiseasesincopdfromdiagnosisandprevalencetotherapy |